Thyroid CancerEECRTKINCT07543887
Selpercatinib and Body Composition
An observational study of Thyroid Cancer, run by University of Pisa at 1 site in Italy.
Trial summary
investigation of body composition Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Thyroid Cancer
- What is being tested?
- observation in patient under treatment and Selpercatinib
- How many people
- 15 participants
- Where
- 1 siteItaly
- Study dates
- 12 Apr 2024to 4 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with thyroid cancer receiving ongoing treatment with selpercatinib
Who may be able to join
- Adults (≥18 years old)
- Diagnosis of thyroid cancer
- Ongoing treatment with selpercatinib
Who cannot join
- Inability to provide informed consent
Trial locations and contacts
1 site in 1 country.
About this study
investigation of body composition
Read the detailed description
investigation of body composition by DXA
- Conditions
- Thyroid Cancer
- Being tested
- observation in patient under treatment, Selpercatinib
- Keywords
- thyroid
- Medical subject headings
- Thyroid Neoplasms, Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observation in patient under treatmentOther
observation in patient under treatment
SelpercatinibDrug
observational study of patients under selpercatinib
| Study group | Role | What they receive |
|---|---|---|
| patient with advanced medullary thyroid cancer | patient with advanced medullary thyroid cancer Receives: Other: observation in patient under treatment; Drug: Selpercatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total lean mass assessed by DXA (kg)
Total lean body mass measured by dual-energy X-ray absorptiometry
Measured: Baseline and 12 months
Secondary outcomes (1)
24-hour energy expenditure (kcal/day)
Total energy expenditure measured over 24 hours using a whole-room indirect calorimeter
Measured: Baseline and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study start12 Apr 2024
- Primary completion4 Apr 2026
- Study completion4 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pisa
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alessio Basolo, University of Pisa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07543887
- Sponsor's protocol ID
- EECRTKI
- Other IDs
- university hospital of pisa
- Acronym
- EECRTKI
- Status last verified
- Apr 2026
- First submitted
- 5 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Selpercatinib and Body Composition
- ClinicalTrials.gov ID
- NCT07543887
- Acronym / sponsor ID
- EECRTKI / EECRTKI
- Conditions
- Thyroid Cancer
- Keywords
- thyroid
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- University of PisaUniversity, hospital or other
- Study start
- 12 Apr 2024 (actual)
- Primary completion
- 4 Apr 2026 (actual)
- Study completion
- 4 Apr 2026 (actual)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
investigation of body composition
Detailed description
investigation of body composition by DXA
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patient with advanced medullary thyroid cancer | – | Other: observation in patient under treatment, Drug: Selpercatinibpatient with advanced medullary thyroid cancer |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with thyroid cancer receiving ongoing treatment with selpercatinib
Key inclusion criteria (3 listed)
- Adults (≥18 years old)
- Diagnosis of thyroid cancer
- Ongoing treatment with selpercatinib
Key exclusion criteria (1 listed)
- Inability to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observation in patient under treatmentobservation in patient under treatment | Other | patient with advanced medullary thyroid cancer |
| Selpercatinibobservational study of patients under selpercatinib | Drug | patient with advanced medullary thyroid cancer |
Primary outcome
Total lean mass assessed by DXA (kg)
Time frame: Baseline and 12 months
Total lean body mass measured by dual-energy X-ray absorptiometry
1 secondary outcome
24-hour energy expenditure (kcal/day)
Time frame: Baseline and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Thyroid Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Recruiting
Ultrasound-guided Microwave Ablation of Benign Thyroid Nodules
Thyroid Nodule (Diagnosis)
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
RecruitingPhase 2
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by University of Pisa at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total lean mass assessed by DXA (kg) (time frame: Baseline and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.